aTyr Pharma Q2 FY26 net loss narrows to $10.31 million

PUBT · 1d ago
aTyr Pharma Q2 FY26 net loss narrows to $10.31 million
  • aTyr Pharma posted a GAAP net loss attributable to shareholders of USD 10.31 million, narrowing from USD 19.53 million a year earlier; GAAP EPS improved to a loss of USD 0.11.
  • GAAP operating loss tightened to USD 10.88 million from USD 20.31 million, while R&D expense fell to USD 6.75 million from USD 15.38 million.
  • Cash, cash equivalents, restricted cash and investments ended June 30 at USD 58.91 million, with runway into late 2028 based on current operations.
  • Restructuring includes a roughly 60% workforce cut, targeting about USD 13 million in annualized operating expense savings starting in Q4 2026.
  • Protocol for a planned Phase 3 efzofitimod study in pulmonary sarcoidosis was submitted in June; FDA feedback is expected by end-August, while SSc-ILD Phase 2 topline data are due in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608071601PRIMZONEFULLFEED9805819) on August 07, 2026, and is solely responsible for the information contained therein.